Table 1 Study characteristics
Authors/year | Country | Perspective | Types of EE | Model type | Study population | Interventiona | Comparator | Type of prophylaxis |
|---|---|---|---|---|---|---|---|---|
Fust et al. 2017 [23] | Belgium | Healthcare payer | CEA and CUA | Markov | 205 elderly patients with aggressive NHL | Pegfilgrastim | 6 and 11 days of filgrastim | Primary and secondary |
Ravangard et al.2017 [33] | Iran | Healthcare payer | CEA | Decision tree | 131 patients with relapsed NHL, aged 19–72 | Pegfilgrastim | 1 and 3 days of filgrastim | Primary |
Wang et al. 2016 [24] | Singapore | Hospital | CEA and CUA | Markov | Hypothetical cohort of 55-year-old patients with NHL | Pegfilgrastim | 7 days of biosimilar filgrastim | Primary and secondary |
Lathia et al. 2013 [19] | Canada | Healthcare payer | CUA | Markov | Hypothetical cohort of 64-year-old patients with DLBCL | Pegfilgrastim | 10 days of filgrastim | Primary |
Perrier et al.2013 [32] | France | Hospital | CEA | Not specified | 151 patients > 18 years with confirmed lymphoma | Pegfilgrastim | Average 6 days of filgrastim | Primary |
Sebban et al.2012 [31] | France | Hospital | CEA | Not specified | 151 patients > 18 years with confirmed lymphoma | Pegfligrastim | Average 6 days of filgrastim | Primary |
Whyte et al. 2011 [21] | UK | Healthcare payer | CUA | Mathematical | Hypothetical patients age of 63 years with aggressive NHL | Pegfilgrastim | 6 and 11 days of filgrastim | Primary and secondary |
Lyman et al. 2009 [22] | USA | Healthcare payer | CEA and CUA | Decision tree | Hypothetical cohort of 65-year-old patients with intermediate- or high-grade NHL | Pegfilgrastim | 6 days of filgrastim | Primary |